The Korea Exchange (KRX) held a corporate review committee on Monday and decided to maintain the listing of Dx&Vx on the tech-heavy Kosdaq market.

With the decision, Dx&Vx's shares resumed trading on Tuesday.

This is the first time in four years since the KRX suspended the trading of the stock in 2019.

Dx&Vx, formerly known as CanceRop, had been at the risk of delisting in 2019 after receiving an adverse opinion from its external auditor for 2018.

The company has since changed its name to Dx&Vx and welcomed Hanmi Science CEO Lim Jong-yoon as its largest shareholder.

"We would like to thank our shareholders for their long-standing confidence in the company, and its employees," Dx&Vx CEO Park Sang-tae said on Monday after the KRX decided to resume trading on the Kosdaq market. "As we prepare to resume trading, we are transforming into a healthcare company that combines diagnostics and solutions."

This year, based on the basic structure of diagnostics and solutions, Dx&Vx plan to conduct basic research and vaccine development specific to bacteria and develop various products based on the basic structure of diagnostics and solutions.

Also, the company will develop new diagnostic technologies and further advance the development of microbiome-based source technologies.

Park also stressed that the company would continue to secure excellent talent as a source of future growth engines and become a company that lays the foundation for expanding the infrastructure of the healthcare industry.

As of 1:00 p.m., the company's shares stood at 6,400 won ($4.93), a 20.99 percent drop from the last trading day in 2019.

Meanwhile, Dx&Vx will hold its shareholders' meeting on Wednesday.